Pharvaris NV
NASDAQ:PHVS
Pharvaris NV
NASDAQ:PHVS
Price:
26.56
USD
0.68%
Market Cap:
$1.7B
Pharvaris NV
EPS (Diluted)
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Pharvaris NV
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharvaris NV
NASDAQ:PHVS
|
EPS (Diluted)
-€2
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Pharvaris NV
Glance View
Pharvaris NV is a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 34 full-time employees. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
PHVS Intrinsic Value
HIDDEN
See Also
What is Pharvaris NV's EPS (Diluted)?
EPS (Diluted)
-2.5
EUR
-2.5
EUR
Based on the financial report for Dec 31, 2024, Pharvaris NV's EPS (Diluted) amounts to -2.5 EUR.
What is Pharvaris NV's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-57%
-57%
Over the last year, the EPS (Diluted) growth was 6%. The average annual EPS (Diluted) growth rates for Pharvaris NV have been -21% over the past three years , -57% over the past five years .
